
Abstract This is an update on the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) contrast enhanced ultrasound (CEUS) non-hepatic applications guidelines, which were last updated in 2017. There has been consolidation of some of the previous applications, particularly, renal and urology, which are now part of routine clinical practice. The highest number of publications and areas of research interest have been in the use of CEUS in bowel, endoscopic ultrasound, and neurosonology. A few novel applications have also been tried and show promise, such as in the parathyroids and salivary glands, while there are a few areas that have previously been researched relatively extensively but are yet to find their clinical utility. Nonetheless, the use of CEUS and its applications has been steadily growing. It is timely that there has been another update on these guidelines which come, as usual, with recommendations on CEUS use from an expert panel.
Abstract Purpose Nasogastric tube (NGT) usage is common among inpatients. However, there is a lack of a convenient and objective tool for assessing a patient’s swallowing function for NGT removal. The feasibility of using submental ultrasound for making decisions regarding NGT removal remains unclear. Materials and Methods This pilot study included patients with NGTs who underwent submental ultrasound examination for NGT removal from March 2023 to December 2025. Patients were divided into derivation and validation cohorts by different examiners. We first measured the resting mandible–hyoid distance and shortest distance when swallowing and then calculated the maximum hyoid bone displacement. Results In the derivation cohort, the maximum displacement was shorter in the NGT group (n = 31) than in the control group (n = 27) (1.26 vs. 1.83 cm, p ≤ 0.001), and the displacement was shorter in the “NGT not removed” subgroup (NG-NR, n = 21) than in the “NGT removed” subgroup (NG-R, n = 10) (1.09 vs. 1.63 cm, p = 0.006). In the validation cohort, the displacement was shorter in the NG-NR subgroup (n = 18) than in the NG-R subgroup (n = 6) (1.36 vs. 1.89 cm, p ≤ 0.001). In the derivation cohort, the displacement showed an AUROC of 0.805 for distinguishing between the NG-NR and NG-R subgroups. A cut-off value of 1.32 cm yielded a sensitivity of 80.0% and a specificity of 81.0%. In the validation cohort, the AUROC was 0.836. In the age- and sex-matched validation cohort, the AUROC was 0.831. The interrater consistency was good. Conclusion Given its good discriminatory performance with regard to NG-R patient identification, interrater consistency, and convenience, submental ultrasound might be an effective screening tool for identifying suitable postacute NGT patients to start swallowing training before NGT removal.
Purpose To evaluate the diagnostic accuracy of Canon Aplio i800 two-dimensional shear wave elastography (2D-SWE) for detecting advanced fibrosis (>= F3) in metabolically associated steatotic liver disease (MASLD) using histology as reference, and to compare its performance with the FIB-4 index. Materials and Methods In this prospective single-center study, 49 patients with MASLD and available liver histology were included. Fibrosis staging (F0-F4) was assessed by three blinded pathologists according to Brown and Kleiner. Shear wave velocity (m/s) served as the primary elastography parameter. Diagnostic performance for >= F3 was assessed by ROC analysis, and clinically applicable rule-in and rule-out thresholds were determined using predefined sensitivity- and specificity-based criteria. Results Advanced fibrosis (>= F3) was present in 15/49 patients (30.6%). 2D-SWE demonstrated an AUROC of 0.88 (95% CI 0.78-0.96) for >= F3, compared with 0.84 (95% CI 0.71-0.96) for FIB-4 (p = 0.39). A threshold of 1.45 m/s (6.3 kPa) achieved 100% sensitivity and negative predictive value. A threshold of 1.85 m/s (11.0 kPa) yielded 94% specificity and 82% positive predictive value. Conclusion Canon Aplio i800 2D-SWE provides robust and clinically applicable, device-specific non-invasive detection of advanced fibrosis in MASLD and supports implementation into guideline-based stepwise risk stratification.